List of Excipients in Branded Drug DEFITELIO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Jazz Pharmaceuticals Inc	DEFITELIO	defibrotide sodium	68727-800	HYDROCHLORIC ACID	2032-06-22
Jazz Pharmaceuticals Inc	DEFITELIO	defibrotide sodium	68727-800	SODIUM HYDROXIDE	2032-06-22
Jazz Pharmaceuticals Inc	DEFITELIO	defibrotide sodium	68727-800	TRISODIUM CITRATE DIHYDRATE	2032-06-22

Defitelio Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Defitelio is an intravenous defibrotide sodium product with a simple, preservative-free aqueous formulation. Its commercial protection depends less on excipient innovation than on manufacturing consistency, impurity control, clinical supply reliability, regulatory approvals, and the ability to supply hospitals treating a rare, high-mortality complication of hematopoietic stem-cell transplantation. The strongest excipient opportunities are differentiated presentations, container-closure improvements, stability enhancement, and hospital-use simplification rather than a conventional reformulation built around novel inactive ingredients.

What is Defitelio and how is it formulated?

Defitelio contains defibrotide sodium, a polydisperse mixture of predominantly single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It is approved for the treatment of hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome, with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation.[1]

Defitelio formulation profile

Attribute	Defitelio profile
Active ingredient	Defibrotide sodium
Dosage form	Concentrate for solution for intravenous infusion
Strength	80 mg/mL
Vial size	2.5 mL single-use vial
Dose	6.25 mg/kg every six hours
Administration	Intravenous infusion over approximately two hours
Daily dose	25 mg/kg/day
Key excipients	Sodium citrate dihydrate, hydrochloric acid, sodium hydroxide, and water for injections
Preservative	None
Dilution media	0.9% sodium chloride or 5% dextrose solution
Typical final concentration	Approximately 4 to 20 mg/mL
Storage	Refrigerated storage before preparation, according to the applicable product label

The formulation uses sodium citrate as the principal buffering component. Hydrochloric acid and sodium hydroxide provide pH adjustment. The product does not rely on surfactants, polyols, antioxidants, antimicrobial preservatives, or complex solubilizers.[1,2]

The formulation is therefore technically conventional but commercially sensitive. Defibrotide is a heterogeneous oligonucleotide mixture, and changes in pH, ionic strength, temperature, container materials, or dilution conditions can affect product quality, aggregation, degradation, or analytical comparability.

What excipients protect Defitelio stability and manufacturability?

The key excipient strategy is pH and ionic-environment control.

Sodium citrate

Sodium citrate dihydrate provides buffering capacity and helps maintain the formulation within the target pH range. Citrate is also familiar to regulators and hospital pharmacies, which reduces excipient-related development risk.

The principal commercial value of citrate is not exclusivity. It is process control. Variability in citrate concentration, grade, hydration state, or supplier quality can affect pH, osmolality, conductivity, and the behavior of the defibrotide mixture during manufacture and dilution.

Hydrochloric acid and sodium hydroxide

These ingredients are pH-adjusting agents rather than primary formulation platforms. Their concentration and addition sequence can affect local pH excursions during compounding. Manufacturing controls should address:

• Order of addition
• Mixing time and shear
• Local concentration gradients
• Temperature during pH adjustment
• Final pH after sterile filtration
• Hold-time stability before filling

Water for injections

Water quality directly affects bioburden, endotoxin, conductivity, and the reproducibility of the final product. Since Defitelio is administered intravenously to severely ill patients, water-system qualification and microbial-control strategy are central parts of the manufacturing package.

Absence of preservatives

The preservative-free design is appropriate for a single-use intravenous vial and avoids compatibility and toxicity questions associated with benzyl alcohol, phenol, parabens, or other antimicrobial agents. A multidose presentation would create a substantially more difficult regulatory and microbiological profile.

What excipient-based commercial opportunities exist for Defitelio?

The best opportunities are presentation and process improvements that preserve the approved formulation or minimize clinical bridging.

Ready-to-dilute or ready-to-use presentations

Defitelio requires dilution before infusion. A ready-to-dilute bag or pharmacy-ready container could reduce preparation time and dosing errors. The development burden would include:

• Stability in the final infusion container
• Compatibility with infusion bags and tubing
• Adsorption or binding to container surfaces
• Particulate and extractables testing
• Light and temperature stability
• Validated in-use storage periods
• Sterility assurance through the extended handling period

A ready-to-use product could support hospital contracting and premium pricing, but the commercial market is limited by the rarity of the indication.

Higher-concentration presentations

A higher-concentration vial could reduce infusion volume and shipping costs. The main technical risks are viscosity, local concentration effects, aggregation, container interaction, and dose-measurement errors. Any increase in concentration would likely require comparative stability, analytical comparability, and potentially clinical bridging.

Alternative buffer systems

Phosphate, histidine, acetate, and other buffers could be evaluated, but replacement of citrate would have limited commercial value unless it materially improves stability, compatibility, or manufacturing yield. A buffer change could alter the product's physicochemical environment and create a new formulation regulatory package.

The strongest rationale for a buffer change would be a demonstrated improvement in:

• Long-term refrigerated stability
• Room-temperature excursion tolerance
• Freeze-thaw resistance
• Resistance to container adsorption
• Compatibility with ready-to-use infusion systems
• Reduction of visible or subvisible particles

Without one of these benefits, a new buffer would add regulatory risk without creating a strong market advantage.

Low-temperature and excursion-stable formulations

Hospitals and distributors benefit from products that tolerate short temperature excursions. An excipient system that extends room-temperature stability could reduce wastage and improve global distribution. Such a claim would require real-time and accelerated stability data, validated excursion conditions, and a clear link between the formulation and product quality.

Container-closure optimization

For Defitelio, packaging may offer more practical value than a new excipient. Relevant options include:

• Low-binding glass vials
• Improved elastomer stoppers
• Reduced extractables and leachables
• Alternative vial coatings
• Prefilled infusion containers
• Smaller vial configurations to reduce residual drug loss

A container-closure patent could provide a more defensible commercial position than a routine excipient substitution, particularly if it addresses adsorption, particulate formation, or dose recovery.

What manufacturing and intellectual-property barriers affect Defitelio?

The principal manufacturing barrier is control of the active substance. Defibrotide is not a conventional small molecule with a single defined molecular structure. Its composition is characterized through source material, production process, molecular-weight distribution, nucleotide composition, purity profile, and biological or functional assays.

Active-substance manufacturing controls

A competing manufacturer would need to establish control over:

• Source and qualification of porcine mucosal DNA
• Enzymatic or chemical processing conditions
• Depolymerization profile
• Molecular-weight distribution
• Residual proteins and nucleotides
• Endotoxin and bioburden
• Viral and adventitious-agent controls
• Batch-to-batch comparability
• Potency and identity assays

These controls create a higher barrier than the excipient formula alone. A generic applicant could replicate citrate-buffered aqueous presentation while still facing difficulty demonstrating equivalence in the active ingredient.

Excipient and process patents

The commercial IP review should separate four categories:

IP category	Relevance to Defitelio
Active ingredient or composition	May cover defibrotide, its salt, composition profile, or pharmaceutical use
Formulation	May cover concentration, pH, buffer, stability, or infusion composition
Manufacturing	May cover production, purification, depolymerization, or characterization
Presentation	May cover vial, infusion bag, dosing system, or storage configuration

A freedom-to-operate review should include U.S. patents, European national validations, the Unified Patent Court register where applicable, PCT filings, continuations, divisionals, and patent-term adjustments. The FDA Orange Book should be checked for current listed patents and regulatory exclusivities associated with NDA 206162.[3]

When did Defitelio lose market exclusivity?

U.S. orphan-drug exclusivity began with FDA approval on March 30, 2016 and generally ran for seven years, subject to the scope of the approved indication. The orphan period therefore reached its ordinary endpoint in March 2023.[1]

Orphan exclusivity is not the same as patent protection. It prevents FDA approval of another product for the same orphan indication during the exclusivity period, subject to statutory exceptions. It does not prevent approval of products for different indications.

The European Union granted marketing authorization in 2013. The relevant EU orphan framework generally provides 10 years of market exclusivity, potentially extended by two years for an agreed pediatric investigation plan. The precise end date depends on the applicable orphan designation and pediatric records held by the European Commission and European Medicines Agency.[2]

Defitelio exclusivity timeline

Event	Date or period
EU marketing authorization	2013
U.S. FDA approval	March 30, 2016
U.S. orphan exclusivity	Generally through March 2023
U.S. NCE exclusivity	Not the principal protection cited for Defitelio
EU orphan exclusivity	Generally 10 years from EU authorization, subject to applicable extensions
Current commercial barrier	Manufacturing, regulatory approval, supply reliability, and any surviving patent rights

Are there Paragraph IV challenges to Defitelio?

A Paragraph IV challenge would require an ANDA applicant to certify that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The commercial relevance of Paragraph IV litigation depends on whether FDA lists enforceable patents for NDA 206162 and whether those patents cover the proposed generic's formulation, method of use, or manufacturing process.[3]

Defitelio's formulation is comparatively straightforward, but the active ingredient is more difficult to reproduce and characterize than a standard synthetic small molecule. A Paragraph IV strategy would therefore likely focus on:

• Formulation equivalence
• Buffer and pH limitations
• Concentration and dilution conditions
• Method-of-use claims
• Process claims that may not be directly infringed by an ANDA product
• Non-infringement positions based on different manufacturing steps

No reliable commercial assessment should treat orphan-exclusivity expiry as proof of immediate generic entry. A generic applicant still must obtain FDA approval, establish active-ingredient comparability, validate manufacturing, and manage hospital adoption.

Is biosimilar risk relevant to Defitelio?

No. Defitelio is a drug product, not a therapeutic protein or other biological product regulated through the biosimilar pathway. The relevant U.S. pathway is generally an ANDA under section 505(j), or potentially a 505(b)(2) application for a materially different formulation, presentation, or route.[4]

A 505(b)(2) strategy could be relevant for:

• Ready-to-use infusion products
• A different container system
• A new concentration
• Extended stability
• A modified administration format
• A formulation with clinical or handling advantages

A 505(b)(2) product would not automatically avoid all patent or exclusivity issues. Its commercial case would depend on a meaningful advantage over the reference product.

Which company controls Defitelio commercialization?

Defitelio originated with Gentium, which Jazz Pharmaceuticals acquired in 2014. Jazz commercialized Defitelio in the United States and has reported it within its oncology or hematology portfolio rather than as a consistently separately disclosed revenue line.[5]

The absence of separately reported product revenue limits precision in estimating brand exposure. The key commercial variables are the small eligible patient population, high treatment cost, hospital reimbursement, treatment-center concentration, and the limited number of specialized competitors.

What generic launch scenarios exist for Defitelio?

Scenario 1: No near-term generic

The reference product retains commercial share because active-substance characterization, manufacturing validation, and specialist-market access deter entry. This is the most favorable scenario for the incumbent.

Scenario 2: Single ANDA entrant

A single approved generic could pressure price while the originator retains share in major transplant centers. The impact would depend on payer substitution, hospital purchasing contracts, and whether the generic matches the reference product's vial size and supply reliability.

Scenario 3: 505(b)(2) formulation entrant

A differentiated infusion product could compete through lower preparation burden, better stability, or reduced waste. This route would require greater investment but could support a premium relative to a basic generic.

Scenario 4: Multiple generic entrants

Price erosion would accelerate if several suppliers obtain approval. Manufacturing scale, active-substance sourcing, quality history, and reliable distribution would become more important than excipient differentiation.

How strong is the Defitelio patent estate?

The formulation itself appears technically narrow: an aqueous defibrotide sodium concentrate using citrate buffering and pH adjustment. That structure may be difficult to defend through broad excipient claims alone because citrate-buffered injectable formulations are familiar pharmaceutical technology.

Potentially stronger protection may arise from:

• Defibrotide active-substance composition and characterization
• Specific manufacturing or purification processes
• Stability profiles tied to defined process conditions
• Combination or method-of-use claims
• Specialized presentations that reduce adsorption or improve dosing

Patent strength should be scored claim by claim. Broad claims covering the active mixture may face validity and prior-art scrutiny. Narrow process claims may be easier to defend but harder to enforce against a competitor using a different manufacturing route. Formulation claims have commercial value only if the accused product necessarily practices the claimed pH, concentration, buffer, or stability limitations.

Key Takeaways

• Defitelio uses a simple preservative-free citrate-buffered intravenous formulation.
• The principal excipients are sodium citrate dihydrate, hydrochloric acid, sodium hydroxide, and water for injections.
• The best commercial opportunities are ready-to-use presentations, improved container systems, reduced residual loss, and temperature-excursion stability.
• Excipient substitution alone is unlikely to create a strong commercial moat.
• The main entry barrier is production and characterization of the heterogeneous defibrotide active substance.
• U.S. orphan exclusivity generally ended in March 2023.
• Biosimilar risk does not apply; ANDA and 505(b)(2) pathways are the relevant U.S. routes.
• The FDA Orange Book and current patent registers should control any final Paragraph IV or freedom-to-operate conclusion.
• Jazz's publicly reported financial disclosures do not consistently isolate Defitelio revenue, limiting product-level revenue exposure analysis.

FAQs

Can Defitelio be reformulated without new clinical trials?

A minor formulation or container change may be supported through pharmaceutical development, stability, and comparability data. A new concentration, administration format, or clinically meaningful excipient change could require additional clinical or bridging evidence.

Could a preservative be added to Defitelio?

A preservative could create a multidose or extended-use presentation, but it would introduce toxicology, compatibility, sterility, and regulatory burdens. The current single-use design makes a preservative-free strategy more practical.

Does citrate create a defensible patent position for Defitelio?

Citrate alone is unlikely to provide strong exclusivity. A defensible claim would need to tie the buffer to a specific concentration, pH range, stability result, container interaction, or manufacturing advantage.

Is a ready-to-use Defitelio infusion bag commercially attractive?

It could be attractive to transplant centers by reducing pharmacy preparation and dosing errors. Its value would depend on demonstrated stability, compatibility, lower wastage, and reimbursement acceptance.

What is the most important diligence issue for a Defitelio generic?

The critical issue is whether the applicant can source and manufacture a defibrotide active substance that matches the reference product's composition, molecular-weight distribution, impurity profile, potency, and quality attributes.

References

1. U.S. Food and Drug Administration. (2023). Defitelio (defibrotide sodium) injection: Prescribing information. Jazz Pharmaceuticals.

2. European Medicines Agency. (2016). Defitelio: EPAR - product information. European Medicines Agency.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). U.S. Department of Health and Human Services.

5. Jazz Pharmaceuticals plc. (2023). Annual report on Form 10-K. U.S. Securities and Exchange Commission.